Ropinirole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Ropinirole is a non-ergot dopamine agonist selective for D2/D3 receptors, approved for Parkinson's disease and moderate-to-severe restless legs syndrome. Similar to pramipexole, it provides an alternative to levodopa in early PD and supplements levodopa therapy in advanced disease to smooth motor fluctuations.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Ropinirole is a non-ergot dopamine agonist selective for D2/D3 receptors, approved for Parkinson's disease and moderate-to-severe restless legs syndrome. NutriStack rates the supporting evidence as strong. Common adult dosing is 0.25 mg three times daily initially, titrated to 3-8 mg three times daily for PD; 0.25-4 mg once daily 1-3 hours before bedtime for RLS (as prescribed by your physician), though a prescriber sets the actual dose. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: effective monotherapy in early parkinson's disease, reduces levodopa dose requirements in advanced pd, fda-approved for restless legs syndrome. 10 sources indexed (2003–2024), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Acts as a full agonist at D2 and D3 dopamine receptors in the caudate-putamen of the striatum, mimicking the effects of endogenous dopamine. Provides continuous dopaminergic stimulation in contrast to the pulsatile stimulation of levodopa. Has negligible affinity for D1, 5-HT, or adrenergic receptors, contributing to its selectivity.
Dosing & protocol.
Bioavailability ~50% due to first-pass metabolism; taking with food reduces nausea. Extensively metabolized by CYP1A2, smoking and ciprofloxacin significantly affect levels.
Full safety detail.
Side effects
- Nausea and vomiting
- Somnolence and sudden sleep attacks
- Dizziness
- Orthostatic hypotension
- Impulse control disorders (gambling, hypersexuality, compulsive eating)
- Hallucinations
- Leg edema
- Augmentation in RLS with long-term use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysisPMIDSoileau LG, Talbot NC, Storey NR et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
Soileau LG, Talbot NC, Storey NR et al.. Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2024
- 2The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysisPMIDZhu J, Chen M · Medicine · 2021
Zhu J, Chen M. The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta-analysis. Medicine. 2021
- 3Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-AnalysisPMIDKurin M, Bielefeldt K, Levinthal DJ · Digestive diseases and sciences · 2018
Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. Digestive diseases and sciences. 2018
- 4Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndromePMIDQuilici S, Abrams KR, Nicolas A et al. · Sleep medicine · 2008
Quilici S, Abrams KR, Nicolas A et al.. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep medicine. 2008
- 5Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysisPMIDEtminan M, Gill S, Samii A · Drug safety · 2003
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug safety. 2003
Reference material
5- 6Rascol O et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484-1491.Source linkedPMID
- 7Trenkwalder C et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study. Mov Disord. 2004;19(12):1414-1423.Source linkedPMID
- 8Pahwa R et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108-1115.Source linkedPMID
- 9Rewane A, Patel P, Nagalli S. Ropinirole. 2026Source linkedPMID
- 10Morimoto S, Takahashi S, Ito D et al.. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell stem cell. 2023Source linkedPMID
Common questions.
Quick answers about Ropinirole, drawn from the data on this page.
What is Ropinirole?
Ropinirole is a non-ergot dopamine agonist selective for D2/D3 receptors, approved for Parkinson's disease and moderate-to-severe restless legs syndrome. Similar to pramipexole, it provides an alternative to levodopa in early PD and supplements levodopa therapy in advanced disease to smooth motor fluctuations.
What is Ropinirole used for?
Commonly cited benefits of Ropinirole include: Effective monotherapy in early Parkinson's disease; Reduces levodopa dose requirements in advanced PD; FDA-approved for restless legs syndrome; Non-ergot structure eliminates fibrotic complication risk. NutriStack rates the overall evidence as strong.
What is a typical dose of Ropinirole?
A typical adult dose of Ropinirole is 0.25 mg three times daily initially, titrated to 3-8 mg three times daily for PD; 0.25-4 mg once daily 1-3 hours before bedtime for RLS (as prescribed by your physician). The commonly recommended form is Immediate-release tablets; extended-release tablets (Requip XL) for once-daily dosing. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Ropinirole?
Reported side effects include nausea and vomiting, somnolence and sudden sleep attacks, dizziness, orthostatic hypotension, impulse control disorders (gambling, hypersexuality, compulsive eating), hallucinations. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Ropinirole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Ropinirole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.